Medigene announces milestone payment in phase I/II trial with dendritic cell (DC) vaccines for AML

Payment of EUR 700,000 to be made through the issuance of new shares

18-May-2015 - Germany

Medigene AG has announced that the progress achieved in its recently initiated clinical phase I/II trial with dendritic cell (DC) vaccines for the treatment of acute myeloid leukaemia (AML) gives rise to a milestone payment amounting to EUR 700,000 to former contributing shareholders of Medigene Immunotherapies GmbH (formerly: Trianta Immunotherapies GmbH) to be made within the next five months. Medigene intends to settle this payment through the issuance of new shares from authorised capital. The milestone payment was an agreed part of the purchase price in the acquisition of Trianta in January 2014.

Medigene's phase I/II multi-centre, open-label trial will include a total of 20 AML patients after completion of standard chemotherapy to reduce the risk of recurrence of leukaemia by using Medigene's DC vaccines. To date, the first patients have been enrolled and a number of additional patients have been identified for inclusion in the trial. The primary objective is to prove feasibility and safety of active immunotherapy with Medigene's DCs. Secondary objectives are induction of immune responses, control of minimal residual disease (MRD) and clinical response/time to progression (TTP).

Dr Frank Mathias, Chief Executive Officer (CEO) of Medigene AG, comments: "Reaching this milestone is once again proof of the progress Medigene has made since acquiring Trianta. The start and continuation of the clinical phase I/II trial enables us to further validate our new generation of DC vaccines in the clinic and will therefore contribute to the intrinsic value of this technology and our company."

Further studies utilizing Medigene's DC vaccine technologies include two ongoing clinical investigator-initiated trials (IITs), a clinical phase II trial (prostate cancer) at Oslo University Hospital and a clinical phase I/II trial (AML) at the Ludwig-Maximilians University Hospital Großhadern, Munich, as well as a compassionate use programme including patients with diverse malignancies.

https://www.bionity.com/en/news/152854/medigene-announces-milestone-payment-in-phase-i-ii-trial-with-dendritic-cell-dc-vaccines-for-aml.html